



JC04 Rec'd PCT/PTO 27 JUN 2005 *PCT*

Practitioner's Docket No. 2002FR302

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IPW

In re application of: Albalat et al.

Application No.: 10/523,734

Group No.:

Filed: January 28, 2005

For: Process For The Preparation of Primary Amines

Commissioner for Patent

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

CERTIFICATION UNDER 37 C.F.R. Sections 1.8(a) and 1.10*
(When using Express Mail, the Express Mail label number is **mandatory**;
Express Mail certification is optional.)

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. section 1.8(a)

37 C.F.R. section 1.10*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"
Mailing Label No. _____ (mandatory)

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office (703) _____.

Date: June 24, 2005

Jackie L. Wise
Signature

Jackie L. Wise
(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b).
"Since the filing of correspondence under [section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Dear Sir:

In accordance with the duty of disclosure provisions of 37 CFR §1.56, there is hereby provided certain information which the Examiner may consider material to the examination of the subject U.S. patent application. It is requested that the Examiner make this information of record if it is deemed material to the examination of the subject application. No admission is made that the information cited in this Statement is, or is considered to be, material to patentability nor a representation that a search has been made (other than search report(s) from a counterpart foreign application or a PCT International Search Report, if submitted herewith).

1. ☒ Enclosures accompanying this Information Disclosure Statement are:
 - 1a. ☒ Form PTO-1449.
 - 1b. ☒ Copies of Information Disclosure Statement citations.
 - 1c. ☐ PCT Search Report
 - 1d. ☐ Copies of Co-pending U.S. Applications.
2. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(b) with the filing of the U.S. patent application. Accordingly, no fee or §1.97(e) Statement is required.
3. ☒ This Information Disclosure Statement is filed under 37 CFR §1.97(b) before the latter of three months after the U.S. patent application filing date or the first Office Action on the merits. Accordingly, no fee or §1.97(e) Statement is required.
4. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(c) after the first Office Action on the merits, but before a Final Office Action or a Notice of Allowance. The \$180.00 fee set forth in 37 CFR §1.17(p) in accordance with 37 CFR §1.97(c) is to be charged to Deposit Account No. 03-2060.
5. ☐ This Information Disclosure Statement is filed under 37 CFR §1.97(e) in that each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Accordingly, no fee is required.
6. ☐ This Information Disclosure Statement is filed in conjunction with a Request For Continued Examination. Accordingly, no fee or §1.97(e) Statement is required.

7. ☐ The English language documents identified by reference in the TRANSLATION Section of the foreign patents list of the attached 1449 Form are believed to be a concise statement, or the equivalent or substantial equivalent to the foreign language documents cited in the attached 1449 Form.
8. ☐ In addition to the documents cited, the Office's attention is directed to the following co-pending U.S. Application Serial Number(s), copies of which are attached for the convenience of the Office:
9. ☒ The Document entitled, "Ueber die Einwirkung von Hydrazin auf Imidoather" discloses the quaternization of compounds with agents for the quaternization of a nitrogen.

Respectfully submitted,



Anthony A. Bisulca
Registration No. 40,913

CUSTOMER NO. 25,255

Clariant Corporation
Industrial Property Department
4000 Monroe Road
Charlotte, North Carolina 28205
Telephone: 704/331-7151
Facsimile: 704/331-7707



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR 1.98(b))	ATTY. DOCKET NO. 2002FR302	SERIAL NO. 10/523,734
	APPLICANT: Albalat et al.	
	FILING DATE: 1/28/2005	GROUP:

U.S. PATENT DOCUMENTS

Examiner Initial		Patent Number	Issue Dte	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
FOREIGN PATENT OR PUBLISHED FOREIGN APPLICATION							
		DOCUMENT NUMBER	PUB. DATE	COUNTRY			TRANSLATION
	BA						
	Bθ						
	BC						
	BO						
	BE						
	BF						
	BC						
	BH						
	BI						
	BJ						
	BK						
	BL						
	BM						
	BN						
	BO						
	BP						
	BQ						
	BP						
	BS						
	BT						
	BU						
	BV						
	BW						
	BX						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication**)

CA	PCT ISR for PCT/IP03/03398, 11/26/2003
CB	Katritzky et al., "Synthesis & Highly Diastereoselective Alkylation of Chiral N-[(s,s)-3,5-Bis(1-methoxyethyl)-1,2,4-triazol-4-yl] arylimines" Tetrahedron: Assymetry, vol. 7, No. 6, pp. 1621-1630 (1996).
CC	Enders et al., "Enantioselektive Synthesen von α -substituierten primären Aminen durch nucleophile addition an SAMP-Hydrazone von Aldehyden," Agnew. Chem. 98, pp 1118-1119 (1986).
CD	Database Crossfire Beilstein "Online. Beilstein Institut zur Forderung der Chemischen Wissenschaften, Frankfurt AM Main, DE XP002239352(1988).
CE	Pragst et al, "Investigations about the cleavage of some pyridinium & Triazolium Ions" J. Prakt. Chem. Vol. 329, No. 6 pp. 1076-1086, XP0001091247 (1987).
CF	Enders, "Alkylation of Chiral Hydrazones," Assymmetric Synthesis Volume 3, Academic Press Inc, pp. 275-338 (1984).
CG	Pinner, "Ueber die Einwirkung von Hydrazin auf Imidoather," Chem Ber. pp 984-1009 (1894)
CH	Advanced Organic Chemistry, Reactions, Mechanisms and Structure, John Wiley & Sons, 4 th ed. 6-35 pp 934-935 (1992).
CI	Advanced Organic Chemstry, Reactions,, Mechanisms, Structure; John Wiley & Sons 6-26, p 918 (1992).
CJ	Advanced Organic Chemistry, Reactions, Mechanisms Structure; John Wiley & Sons 9-51, p. 1219 (1992).
CK	Martinez-Diaz et al., "Preparation & Enantiomeric Purity Determination of New Chiral C2 Building Blocks Based on the 4-Amino-1,2,4-triazole Unit," Tetrahedron: Assymetry Vol 5. No. 7 pp. 1291-1296 (1994).
CL	Matsuda et al, "Reaction of 4-Amino-1,2,4-Triazolium Salts w/ Polarized Olefins," Heterocycles, Vol. 41, No. 12, pp 2777-2784 (1995).
CM	Alonzo et al., "Proton-Ionizable Macrocycles Containing 1,2,4-Triazole and 4-amino-1,2,4-triazole Subunits," Heterocycles, Vol. 26, No. 4, pp. 989-1000 (1987).
CN	Glover et al., "Sythesis of 1,1'-Dimethyl-4,4'-azo-1,2,4-triazolium and 3,3'-Dimeththyl-1,1'-azobenzotriazolium Salts," J. Chem. Soc. Perkins Trans. 1 pp 1792-1794 (1974).
CO	Becker et al., "Azocoupling of Quaternary 1,2,4-Triazolium Salts to form 5-p-N,N-Dimethylaminophenylazo-1,2,4-triazolium Salts," Journal fur Praktische Chemie 330 pp 325-337 (1988).
CP	Alcalde et al., "Non-classical [14] Metaheterophanes Containing Betaine Units. Synthesis NMR Spectroscopy & X-Ray Crystallography," J. Chem. Soc., Chem. Commun pp 1239-1240 (1995).
CQ	
EXAMINER	
DATE CONSIDERED	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

